Seres Therapeutics (NASDAQ:MCRB) is a pioneer in the emerging field of live biotherapeutic products, medicines made from communities of bacteria, now concentrating its efforts on a candidate designed to prevent dangerous infections in vulnerable patients. The company is balancing promising clinical data against a …
IceCure Medical (NASDAQ:ICCM) is building the kind of early commercial momentum that can change how investors view a small medical-device company. The Israel-based maker of cryoablation systems, technology that destroys tumors by freezing them, has been expanding its U.S. presence rapidly since securing a …
●Telehealth access:On July 6, 2026, LENZ announced a new telehealth prescribing option intended to accelerate patient access to VIZZ.
●New licensing deal:On August 11, 2026, Mereo announced an option and license agreement with Sentynl Therapeutics covering U.S. rights to alvelestat.
● enVVeno reported second-quarter 2026 financial results and advances toward an FDA pivotal trial for its first-in-class replacement venous valve.
Phreesia (NYSE:PHR), a healthcare-technology company that helps medical practices manage patient intake, scheduling and payments, has reached an important milestone: profitability. After years of prioritizing growth, the company crossed into positiveNet Incomewhile continuing to expand revenue.
ADC Therapeutics (NYSE:ADCT) is working to build on its approved lymphoma treatment while advancing a pipeline of antibody-drug conjugates. The company reported second-quarter 2026 results that narrowed its loss, though questions around a key confirmatory study tempered the picture.
Atossa Therapeutics (NASDAQ:ATOS) is advancing a differentiated approach to breast-cancer treatment and prevention. The company is building a body of evidence for its lead candidate across multiple settings, with the path forward running through clinical data and regulatory progress.
●Pediatric designation plans:On June 18, 2026, Cadrenal announced plans to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease.
● The company's lead drug simufilam failed to demonstrate benefit in Alzheimer's disease trials.